View Older Stories

Feb 24, 2026 09:08AM Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

Feb 4, 2026 08:30AM SAREPTA gets approval to test Huntington's disease treatment in humans

Jan 27, 2026 06:43AM JPMorgan on Sarepta Therapeutics (SRPT): 'Quick Thoughts On Elevidys 3-Year EMBARK Data'

Jan 26, 2026 12:54PM Sarepta Therapeutics (SRPT) PT Raised to $22 at Baird

Jan 26, 2026 08:01AM Sarepta reports positive three-year results for Duchenne gene therapy

Jan 26, 2026 05:30AM Sarepta Therapeutics (SRPT) call put ratio 1.7 calls to 1 put into presenting three-year results from its EMBARK study of ELEVIDYS

Jan 26, 2026 05:18AM RBC Capital on Sarepta (SRPT): 'KOL Feedback Suggests Elevidys Use Unlikely To Pick Back Up in '26'

Jan 23, 2026 04:05PM Sarepta to present 3-year ELEVIDYS gene therapy data on Jan. 26

Jan 14, 2026 06:55AM H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT)

Jan 14, 2026 04:39AM Mizuho Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)

Jan 12, 2026 11:59AM Sarepta reports $1.86 billion in 2025 product revenue

Jan 12, 2026 09:30AM Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty

Jan 8, 2026 03:59AM Leerink Partners Reiterates Market Perform Rating on Sarepta Therapeutics (SRPT)

Jan 7, 2026 08:31AM Sarepta submits clinical trial application for Huntington's disease drug

Dec 11, 2025 11:53AM Mizuho on Sarepta Therapeutics (SRPT): 'See Today's Weakness as Buying Opportunity'

Dec 9, 2025 06:50AM Wedbush Starts Sarepta Therapeutics (SRPT) at Outperform

Nov 25, 2025 08:58AM Sarepta receives FDA approval for ELEVIDYS study with enhanced immunosuppression

Nov 25, 2025 07:31AM Sarepta Therapeutics (SRPT) PT Raised to $20 at Bernstein SocGen Group

Nov 24, 2025 07:31AM Sarepta advances SRP-1003 trial, triggers $200 million milestone payment

Nov 24, 2025 07:30AM Arrowhead Pharmaceuticals receives $200 million from Sarepta milestone

Nov 20, 2025 03:59AM Mizuho Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)

Nov 14, 2025 02:59PM FDA approves updated ELEVIDYS label with liver injury warning

Nov 14, 2025 02:02PM FDA approves new safety warning and revised indication that limits use for Elevidys following reports of fatal liver injuryHHS: FDA approves new safety warning and revised indication that limits

Nov 5, 2025 10:07AM Mizuho upgrades Sarepta on confidence in Elevidys uptake

Nov 5, 2025 04:33AM Mizuho Upgrades Sarepta Therapeutics (SRPT) to Outperform

Nov 4, 2025 05:13AM Sarepta Therapeutics (SRPT) PT Lowered to $15 at Baird

Nov 3, 2025 04:41PM After-hours movers: Palantir, Hims & Hers Health, Sarepta Therapeutics, Sanmina

Nov 3, 2025 04:17PM Sarepta Therapeutics (SRPT) Tops Q3 EPS by 57c

Nov 3, 2025 04:13PM Sarepta completes confirmatory study for duchenne therapies, study misses primary endpoint

Oct 8, 2025 12:07PM Jefferies Reiterates Buy Rating on Sarepta Therapeutics (SRPT), 'Several Dynamics to Follow But Optics Could Further Improve in 2026'

Oct 7, 2025 06:37AM Mizuho Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)

Sep 22, 2025 07:18AM Cantor Fitzgerald Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)

Sep 22, 2025 05:04AM BMO Capital Upgrades Sarepta Therapeutics (SRPT) to Outperform

Sep 16, 2025 05:19AM BMO Capital Reiterates Market Perform Rating on Sarepta Therapeutics (SRPT)

Aug 27, 2025 08:39AM Elanco to join S&P MidCap 400 as Sarepta moves to SmallCap 600

Aug 25, 2025 06:41AM H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT)

Aug 24, 2025 07:06PM Mizuho on Sarepta Therapeutics (SRPT): 'Lowering 3Q25 Elevidys Sales Below Consensus'

Aug 21, 2025 10:16AM Sarepta Therapeutics (SRPT) PT Lowered to $16 at BofA Securities, 'Debt refinancing mitigates liquidity risk but Elevidys launch remains overhang'

Aug 20, 2025 04:23PM Citi Opens 90-Day Downside Catalyst Call on Sarepta Therapeutics (SRPT)

Aug 13, 2025 04:13PM Sarepta sells $174 million in Arrowhead stock, triggers $100 million milestone

Aug 12, 2025 01:25PM Sarepta Therapeutics (SRPT) Declines Again On EMA Recommendation to Refuse ELEVIDYS Marketing Authorization, Securities Class Action Pending - Hagens Berman

Aug 11, 2025 01:59PM Jefferies Reiterates Buy Rating on Sarepta Therapeutics (SRPT)

Aug 11, 2025 01:22PM TD Cowen Reiterates Hold Rating on Sarepta Therapeutics (SRPT)

Aug 11, 2025 10:42AM Freedom Broker Upgrades Sarepta Therapeutics (SRPT) to Buy

Aug 8, 2025 12:22PM Sarepta Therapeutics (SRPT) PT Raised to $14 at Citi

Aug 7, 2025 11:05AM BMO Capital Reiterates Market Perform Rating on Sarepta Therapeutics (SRPT) Following Mgmt. Meeting

Aug 7, 2025 05:47AM Sarepta Therapeutics (SRPT) PT Raised to $50 at Wells Fargo

Aug 6, 2025 04:19PM Sarepta Therapeutics (SRPT) Tops Q2 EPS by $1.32

Aug 5, 2025 06:28PM Sarepta Therapeutics (SRPT) Announces Restructuring and ELEVIDYS Black Box Warning, EMA Recommends Refusal of Marketing Authorization, Securities Class Action Pending - Hagens Berman

Aug 4, 2025 02:26PM RBC Capital weighs in on Sarepta Therapeutics (SRPT) related to two new FAERS Elevidys deaths

View Older Stories